C
CLDX icon

Covestor’s Celldex Therapeutics CLDX Stock Holding History

Covestor’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
18
+12
+200% +$388 ﹤0.01% 2086
2026
Q1 		$0 Sell
6
-2
-25% -$55 ﹤0.01% 2313
2025
Q4 		$0 Sell
8
-2
-20% -$53 ﹤0.01% 2311
2025
Q3 		$0 Buy
10
+5
+100% +$116 ﹤0.01% 2331
2025
Q2 		$0 Sell
5
-4
-44% -$78 ﹤0.01% 2264
2025
Q1 		$0 Buy
9
+3
+50% +$67 ﹤0.01% 2275
2024
Q4 		$0 Buy
6
+3
+100% +$82 ﹤0.01% 2282
2024
Q3 		$0 Hold
3
– – ﹤0.01% 2273
2024
Q2 		$0 Sell
3
-7
-70% -$264 ﹤0.01% 2283
2024
Q1 		$0 Buy
10
+5
+100% +$205 ﹤0.01% 2284
2023
Q4 		$0 Hold
5
– – ﹤0.01% 2191
2023
Q3 		$0 Hold
5
– – ﹤0.01% 2162
2023
Q2 		$0 Hold
5
– – ﹤0.01% 2176
2023
Q1 		$0 Hold
5
– – ﹤0.01% 2074
2022
Q4 		$0 Hold
5
– – ﹤0.01% 2111
2022
Q3 		$0 Sell
5
-1
-17% -$31 ﹤0.01% 2051
2022
Q2 		$0 Sell
6
-2
-25% -$58 ﹤0.01% 1960
2022
Q1 		$0 Sell
8
-2
-20% -$64 ﹤0.01% 2143
2021
Q4 		$0 Buy
+10
New +$436 ﹤0.01% 2136

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Covestor's CLDX Position: Q2 2026 in Review

Covestor increased its Celldex Therapeutics (CLDX) stake by 200% in Q2 2026, buying an estimated $388 and bringing the position to 18 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2086.

Covestor first reported a position in CLDX in Q4 2021 and has held it in 19 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Covestor held 18 shares of Celldex Therapeutics worth $1K as of Q2 2026.
  • Covestor bought 12 Celldex Therapeutics shares in Q2 2026, an estimated $388.
  • Celldex Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2086 holding.
  • Covestor first reported a position in Celldex Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.